Two Case Reports of Leukocytoclastic Vasculitis after ChAdOx1 nCoV-19 Vaccine
- Author:
Hae Eun PARK
1
;
Ju Hee HAN
;
Yeong Ho KIM
;
Ji Hyun LEE
;
Young Min PARK
;
Hwa Young LEE
;
Chul Hwan BANG
Author Information
1. Department of Dermatology and Division of Allergy, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:Case Report
- From:Korean Journal of Dermatology
2022;60(7):444-448
- CountryRepublic of Korea
- Language:English
-
Abstract:
Leukocytoclastic vasculitis after the BNT162b2 vaccine and ChAdOx1 nCoV-19 Corona Virus vaccine [recombinant] has been observed. Herein, we report two cases of leukocytoclastic vasculitis that developed after the ChAdOx1-S [recombinant] vaccination. A 61-year-old and a 52-year-old woman presented with pruritic purpuric macules and papules on both lower legs. The patients had been vaccinated with the ChAdOx1-S [recombinant] vaccine. The histopathological analyses were consistent with a diagnosis of leukocytoclastic vasculitis. They were treated with oral prednisolone and improved within 1 month of treatment. We assume that the rash had arisen from the deposition of spike protein at the skin tissue induced by the viral vector of the COVID-19 vaccine or hyperimmune responses by excipients present in vaccine preparations. To our knowledge, our cases would be the first Korean cases of leukocytoclastic vasculitis after the ChAdOx1-S [recombinant] vaccination.
